Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy has revolutionized hematological malignancy treatment.
• CAR T-cell therapy efficacy is limited in solid tumors, unlike in hematological malignancies like B-ALL.
• The immunosuppressive tumor microenvironment (TME) is hypothesized to impede CAR T-cell function in solid tumors.

Purpose of the Study:

• To review strategies for enhancing CAR T-cell efficacy in solid tumors.
• To explore the interaction between the TME and CAR T-cells.
• To highlight potential combinatorial approaches and their translational potential.

Main Methods:

• Review of recent studies and mouse models.
• Analysis of TME-related challenges to CAR T-cell therapy.
• Evaluation of novel strategies and combinatorial treatments.

Main Results:

• The TME presents significant barriers to CAR T-cell therapy in solid tumors.
• Various strategies are being developed to overcome TME-induced immunosuppression.
• Combinatorial approaches show promise in preclinical mouse models.

Conclusions:

• Overcoming TME-mediated immunosuppression is critical for successful CAR T-cell therapy in solid tumors.
• Further research in mouse models is essential to translate these findings.
• Enhanced CAR T-cell strategies hold potential for treating solid tumors.